Journal of Psychopharmacology · 2018 · 18 citations · 38 references
PharmacyPharmacotherapyPsychiatryNeuropsychiatryPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyLong-acting Injectable AntipsychoticsMedication AdherenceRelapse PreventionSchizophrenia PharmacotherapyAcute Schizophrenia TreatmentAdherence To Antipsychotic TreatmentAntipsychotic AdherenceAntipsychotic EfficacyOpen-label TrialsPost Hoc AnalysisProphylaxis Of RelapsePsychotic Relapse Prevention
BACKGROUND: Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable antipsychotics. AIM: To investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses, factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with schizophrenia. METHODS: This was a post-hoc analysis from an open-label, single-arm study of stable patients (Positive and Negative Syndrome Scale total score <70; n=367) receiving paliperidone palmitate one-month formulation at the end of an acute 13-week treatment phase, who entered a naturalistic one-year follow-up period, either continuing with flexibly dosed paliperidone palmitate one-month formulation (75-150 mg eq.) or switching to another antipsychotic(s). RESULTS: There were 362/367 patients (age=31.4±10.75 years) included in the analysis of time to first relapse (primary outcome) and 327/362 patients (39/327, poor antipsychotic adherence (<80%)) willing to receive antipsychotics were included in the exposure/adherence analysis. Overall, 84.6% (95% confidence interval=79.2-88.7) patients remained relapse-free. Poor adherence during follow-up (hazard ratio=2.97, 95% confidence interval=1.48-5.98, p=0.002) and frequent hospitalizations in the previous year (hazard ratio=1.29, 95% confidence interval=1.02-1.62, p=0.03) were associated with a significant risk of shorter time to first relapse in the univariate analysis. In patients with poor adherence, 'no use' (hazard ratio=13.13, 95% confidence interval=1.33-129.96, p=0.03) and 'interrupted use' (hazard ratio=11.04, 95% confidence interval=1.03-118.60, p=0.047) of paliperidone palmitate one-month formulation (vs continued use) showed a significantly higher risk of relapse; this was not observed in patients with good (≥80%) antipsychotic adherence. No new safety concerns were identified. CONCLUSION: Continued use of paliperidone palmitate one-month formulation/long-acting injectable antipsychotic was effective in preventing schizophrenia relapses, especially in patients with suboptimal antipsychotic adherence.
38
Pier Luigi Morosini, Lorenza Magliano, L Brambilla et al. · PubMed · 2000 · 1.2K citations
Early intervention in psychosis. The critical period hypothesis.
Max Birchwood, Paula Todd, Christopher Jackson · PubMed · 1998 · 761 citations
Medicine, Psychiatry, Psychology +14